houseofthedeadscarletdawnpc| Pharmaceutical Industry Weekly: Phase 3 clinical results of Novartis busizumab are actively used to treat PDR

Market performanceHouseofthedeadscarletdawnpc: on May 9, 2024, the pharmaceutical sector rose and fell by + 0Houseofthedeadscarletdawnpc.93%, outperforming the CSI 300 Index 0Houseofthedeadscarletdawnpc.02pct, ranking 21st in 31 sub-industries. Among the pharmaceutical sub-industries, offline drugstores (+ 2.95%), medical consumables (+ 1.88%) and pharmaceutical circulation (+ 1.87%) were the top performers, followed by in vitro diagnosis (+ 0.19%), medical equipment (+ 0.25%) and other biological products (+ 0.82%). In terms of individual stocks, the top three daily gains were Daga Weikang (+ 20.02%), Conghui Pharmaceutical (+ 10.02%) and Vcanbio (+ 10.01%). The top three declines were Oukang Pharmaceutical (- 9.78%), Guangji Pharmaceutical (- 8.03%) and Youningwei (- 7.43%). Important news of the industryHouseofthedeadscarletdawnpcOn May 9, Novartis announced for the first time the results of the 54-week phase 3 CONDOR clinical trial of busizumab (brolucizumab) and 6mg in the treatment of proliferative diabetic retinopathy (PDR) at the meeting of the Society of Vision and Ophthalmology (ARVO). The data showed that busizumab was significantly superior to traditional therapy in maintaining visual acuity in patients with PDR, which could reverse diabetic retinopathy, and the proportion of patients without PDR at the 54th week was nearly three times that of the control group (63.8% vs 22.4%). Busizumab, a full VEGF-An inhibitor developed by Novartis, is a new humanized scFv fragment with a molecular weight of only 26kDa, high affinity, strong tissue penetration and small systemic side effects. (source: Novartis) Company News: Osaikang (002755): the company announced that Jiangsu Osaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the Drug Registration Certificate of Isaconazole Sulfate for injection approved by the State Drug Administration. The drug is a broad-spectrum new triazole antifungal drug, mainly used in the treatment of invasive aspergillosis and invasive mucormycosis in adult patients. Beilu Pharmaceutical (300016): the company announced that it recently received the Drug Registration Certificate of Paroxetine Hydrochloride enteric-coated sustained-release tablets approved and issued by the State Drug Administration. After examination, the product met the relevant requirements of drug registration and approved registration. Blue Fan Medical (002382): the company announced that three types of medical devices developed and produced by its subsidiary Shanghai Lanfan Boyuan Medical Technology Co., Ltd., "Cardiac Coronary artery Balloon Dilatation Catheter", has been approved and registered by the State Drug Administration (NMPA). The product mainly treats complex coronary artery lesions, including chronic total occlusive disease (CTO). Tuojing Life (300642): the company announced that its subsidiary Shanghai A pre-Life Technology Co., Ltd. recently received an invention patent certificate issued by the State intellectual property Office of the people's Republic of China. The patent provides a device for judging methylation of lung cancer and colorectal cancer. Risk tips: new drug research and development and listing are not as expected; policy promotion is higher than expected; market competition aggravates the risk. [disclaimer] this article only represents the views of a third party and does not represent the position of Hexun. Investors operate accordingly, at their own risk.

[disclaimer] this article only represents the views of a third party and does not represent the position of Hexun. Investors operate accordingly, at their own risk.

Tags:

Prev: lulusarcade| The Bank of England moves towards a rare cycle of slow interest rate cuts
Next: davincidiamondsfreeslots| Yuyuan Shares (600655.SH): Terminate the issuance of A shares to specific targets in 2023 and withdraw the application documents